Group 1 - The core viewpoint of the article highlights the commencement of construction for two key centers by Chengyitong, marking a new phase in the brain-computer interface (BCI) sector [1] - The BCI technology research validation center will focus on cutting-edge theories, key technologies, new materials, and core devices, aiming to create a complete innovation chain from basic research to engineering application [1] - The animal experiment center will provide in vivo research and application validation for core BCI technologies, equipped with facilities for various experimental capabilities, supporting the transition of BCI from laboratory to clinical applications [1] Group 2 - The construction ceremony took place on July 8, 2025, at the Beijing Daxing Biomedical Industry Base, attended by key company executives [1] - The research validation center will conduct studies on neural signal acquisition, processing, and decoding, as well as explore biocompatible materials and closed-loop control algorithms [1] - The animal experiment center will support experiments related to neural coding mechanisms, implantable electrode evaluation, and system integration, facilitating the practical application of BCI technologies [1]

Group 1 - The human brain engineering sector experienced a slight increase of 0.41% on July 11, with a total capital outflow of 583.41 million [1] - A total of 21 stocks in the sector rose, while 8 stocks declined [1] - The top-performing stocks included Meihao Medical (+3.83%), Hanwei Technology (+2.72%), and Zhongke Information (+2.27%) [1] Group 2 - The stocks with the largest declines were ST Huatuo (-3.87%), Pulite (-1.94%), and Aipeng Medical (-1.72%) [1] - The overall market sentiment showed a mixed performance with significant capital movements in both rising and falling stocks [1]

Investment Rating - The investment rating for the computer industry is optimistic (maintained) [1] Core Insights - The brain-computer interface (BCI) market has significant potential, with global medical applications expected to reach $40 billion by 2030 and $145 billion by 2040 [5][36] - The technology is maturing, with companies like Neuralink receiving FDA approval for human trials, indicating a shift from concept to practical application [6][8] - Policy support is increasing, with various regions in China implementing plans to accelerate the commercialization of BCI technologies [7][45] Summary by Sections 1. Brain-Computer Interface: Continuous Breakthrough - BCI creates a communication channel between the brain and external devices, enabling direct information exchange [17] - The global BCI market was valued at $2.35 billion in 2023, with a projected CAGR of 16.55% from 2023 to 2033 [35] 2. Policy and Technology Resonance: Bright Commercial Prospects for BCI 2.1 Policy: BCI Medical Pricing Implementation Accelerates Commercialization - Major countries are investing in BCI research, with the U.S. and EU leading in funding and project initiatives [41][44] - China's government has issued multiple directives to guide BCI development, including the establishment of independent pricing for BCI services [45][46] 2.2 Technology: Positive Progress in Clinical Trials, Approaching Industrialization - The BCI system faces numerous technical barriers, particularly in balancing performance and commercial viability [48] - China's BCI sector is rapidly advancing, with increasing publications and patents in the field [51][52] 3. Beneficiary Companies 3.1 Neuralink: Pioneer in Invasive BCI Technology - Neuralink is leading in invasive BCI technology, having initiated human trials and planning further patient implants [55][66] 3.2 Strong Brain Technology: Leader in Non-Invasive BCI - Strong Brain Technology focuses on non-invasive BCI solutions, having developed multiple products and secured significant funding [67][69] 3.3 Rock Mountain Technology: Forward-Looking Layout of Brainwave Large Models - Rock Mountain Technology is developing brainwave large models to enhance human-computer interaction systems [80]

Group 1 - The core viewpoint of the news is that Chengyitong Group has initiated the construction of a brain-computer interface (BCI) technology research validation center and an animal experimentation center, marking a new phase in the BCI field [1] - The two centers aim to establish a complete innovation chain from basic research to technology validation and result transformation, reinforcing the company's strategic layout in the BCI sector [1][6] Group 2 - The BCI technology research validation center will focus on cutting-edge theories, key technologies, new materials, and core devices in the BCI field, facilitating the exploration of basic mechanisms to engineering applications [3] - Key research areas include neural signal acquisition, processing and decoding, implantable/wearable electrode materials, biocompatible packaging, neural modulation mechanisms, and closed-loop control algorithms [3] - The center aims to integrate disciplines such as neuroscience, electronic information, artificial intelligence, and materials science to become a core technology source for BCI [3] Group 3 - The BCI animal experimentation center will provide in vivo research and application validation for core BCI technologies, capable of conducting experiments on both small rodents and large mammals [4] - Equipped with standardized surgical rooms, electrophysiological recording and stimulation systems, and behavioral experiment platforms, the center supports multi-channel neural signal acquisition, electrode implantation, long-term recording, closed-loop control, and neural modulation experiments [4] - The center will focus on researching neural coding mechanisms, evaluating implantable electrodes, verifying biocompatibility, and coordinating BCI systems for clinical applications [4] Group 4 - Chengyitong Group adheres to the mission of "making manufacturing smarter and making the public healthier," and the construction of the two centers will further enhance its technological innovation capabilities in the BCI field [6] - The company plans to continue investing in research and development to promote the industrial application of BCI technology, injecting new momentum into the development of the healthcare sector [6]

Group 1 - The brain-computer interface concept sector rose by 0.74%, ranking 8th among concept sectors, with 17 stocks increasing in value [1] - Leading gainers in the sector included Jihua Group, Entropy Technology, and Beiyikang, which rose by 7.59%, 5.92%, and 4.33% respectively [1] - The sector experienced a net inflow of 366 million yuan, with 18 stocks receiving net inflows, and 12 stocks seeing inflows exceeding 10 million yuan [1][2] Group 2 - Jihua Group had the highest net inflow of 331 million yuan, followed by Innovative Medical, Chengyitong, and Zhongke Information with net inflows of 162 million yuan, 77.97 million yuan, and 36.04 million yuan respectively [1][2] - The net inflow ratios for Jihua Group, Chengyitong, and Zhongke Information were 13.23%, 10.52%, and 8.87% respectively [2] - The trading volume and turnover rates for leading stocks in the sector were significant, with Jihua Group showing a turnover rate of 13.84% [2][3]

Group 1 - The company approved a profit distribution plan for the year 2024, proposing a cash dividend of RMB 0.45 per 10 shares, totaling RMB 12,287,141.82 (including tax) based on a total share capital of 273,047,596 shares as of the announcement date [1][2] - Following a share cancellation, the total share capital will be adjusted to 273,046,796 shares, but the cash dividend per share will remain unchanged [1][2] - The actual distribution will be based on the total share capital as of the record date, which is set for July 10, 2025, with the ex-dividend date on July 11, 2025 [3] Group 2 - The company will not withhold individual income tax for shareholders, and tax will be calculated based on the holding period when shares are sold [2][3] - Different tax rates will apply for overseas institutions and individual investors holding pre-IPO restricted shares, with a 10% tax rate for Hong Kong investors on fund shares [2][3] - The distribution plan is subject to adjustments if the total share capital changes before the implementation [2]

北京诚益通控制技术集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300430 证券简称：诚益通 公告编号：2025-032 1、北京诚益通控制技术集团股份有限公司（以下简称"公司"）2024 年年 度股东大会审议通过的 2024 年度利润分配方案为：拟以截至披露利润分配方案 公告日的公司总股本 273,047,596 股为基数，向全体股东每 10 股派发现金股利 人民币 0.45 元（含税），合计派发现金股利人民币 12,287,141.82 元（含税）； 2、自 2024 年度利润分配方案披露至实施期间，公司总股本因股权激励回购 注销事项由 273,047,596 股变更为 273,046,796 股，将按照每股分配金额不变， 相应调整分配总额。本次权益分派实施后计算除权除息价格时，按公司最新总股 本折算的每 10 股现金分红=现金分红总额÷总股本（含回购股份）×10 股 =12,287,105.82 元/273,046,796×10 股=0.450000 元（保留六位小数）。本次 ...

| 投资主体 | 受托方 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年化收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | | 类型 | 额（万元） | | | 益率 | | 北京诚益通控 | | | 天添利现金 | | | 2025 年 6 | 2025 年 6 | | | 制技术集团股 | 浦发银行 | 否 | | 现金管理类 | 1750 | | | 1.7%～3% | | | | | 宝 | | | 月 11 日 | 月 26 日 | | | 份有限公司 | | | | | | | | | | 北京诚益通控 | | | | | | 2025 年 6 | 2025 年 6 | 1.80%～ | | 制技术集团股 | 江苏银行 | 否 | 苏银理财恒 | 固定收益类 | 1000 | | | | | 份有限公司 | | | 源灵动 | | | 月 13 日 | 月 23 日 | 2.60% | | 北京诚益通控 制技术集团股 | | | 民生理财天 | | | 2025 年 6 ...

A股市场热点不断，近期，"脑机接口"概念火了。 21世纪经济报道记者注意到，在上周大涨之后，6月23日，脑机接口板块继续上扬，塞力医疗 （603716）（603716.SH）"10CM"涨停，三博脑科（301293）（301293.SZ）涨幅超5%，佳禾智能 （300793）（300793.SZ）、麒盛科技（603610）（603610.SH）涨幅3%以上、诚益通（300430） （300430.SZ）、狄耐克（300884）（300884.SZ）、乐普医疗（300003）（300003.SZ）、熵基科技 （301330）（301330.SZ）涨幅2%以上。 与此同时，投资者涌向上市公司互动平台，密集询问公司脑机接口相关布局。从机构调研的角度看，近 两个月已有不少机构提前嗅到了相关机遇，了解脑机接口相关业务。 就脑机接口的产业链机遇而言，浙商证券（601878）指出，产业应用上，该市场仍以医疗为主。未来在 教育、游戏、智能家居等领域的应用占比将逐步提升。软件层面，人工智能技术的高速发展将为脑机接 口带来更多的创新机会；硬件层面，更高精度的传感器正在被开发，设备越来越轻便、便携，侵入性与 人体的兼容性正在持续改 ...

Group 1 - The brain-computer interface sector experienced a decline of 3.34%, ranking among the top losers in the concept sector as of the market close on June 20 [1][2] - Within the brain-computer interface sector, major companies such as Hanwei Technology, Nanjing Panda, and Aipeng Medical saw significant declines, while only two stocks, Haige Communication and ST Huatuo, recorded gains of 1.46% and 1.05% respectively [1][2] - The sector faced a net outflow of 546 million yuan from main funds, with 23 stocks experiencing net outflows, and seven stocks seeing outflows exceeding 30 million yuan [2] Group 2 - Hanwei Technology led the outflow with a net withdrawal of 133 million yuan, followed by Innovative Medical and Tom Cat with outflows of 129 million yuan and 116 million yuan respectively [2][3] - The stocks with the highest net inflows included ST Huatuo, Haige Communication, and Lepu Medical, with inflows of 58.93 million yuan, 35.06 million yuan, and 23.44 million yuan respectively [2][3] - The trading volume for Hanwei Technology was 12.95%, indicating a high turnover rate despite the decline of 6.59% in its stock price [2][3]